Mirati sees more responses for KRAS drug in Keytruda combo as it angles for an edge over Amgen
With a filing for its KRAS inhibitor adagrasib right around the corner, Mirati is building a growing case against Amgen as investors watch with bated …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
